Ovid takes a novel approach to gene therapy
Ovid and its partner Gensaic have high hopes for a brand-new delivery method, and much to prove.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Aids 2022 preview – Gilead shoots for an HIV cure
But progress – or lack thereof – with lenacapavir is a more immediate concern.
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
Lilly’s oral interleukin exit hints at a dicey future
Liver toxicity with the group’s oral IL-17 inhibitor could raise doubts about projects from Dice, Leo and Sanofi.
